Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 446

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 446
---
 market after our IPO, or the perception that these sales may occur, could materially
and adversely affect the price of our common stock and could impair our ability to raise capital through the sale of additional equity
securities. Those shares of common stock sold in our IPO will be freely tradable, without restriction, in the public market, except for
any shares sold to our affiliates.

After
the date of the IPO, when 1,000,000 shares of common stock became publicly tradable, approximately 23,891,902 additional shares of common
stock were subject to “lock-up” agreements entered into in connection with the IPO, are or will become eligible to be sold
in the public market by existing stockholders by February 9, 2025 as a result of Rule 144 of the Securities Act, subject to volume and
other limitations imposed under the federal securities laws. Furthermore, additional shares of our common stock may be publicly tradable
as a result of exercises of stock options and restricted stock units (RSUs) under the 2023 Omnibus Incentive Plan. Sales of substantial
amounts of our common stock in the public market after the completion of the IPO, or the perception that such sales could occur, could
adversely affect the market price of our common stock and could materially impair our ability to raise capital through offerings of our
common stock.

Because
of the speculative nature of an investment in our company, you may lose your entire investment.

An
investment in our securities carries a high degree of risk and should be considered as a speculative investment. We have a very limited
operating history, are in the pre-clinical stage of development of our product candidate, have never generated revenues, have not paid
dividends, and are unlikely to pay dividends in the immediate or near future. The likelihood of our being able to achieve our goals and
run our business must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered
in connection with the establishment of early-stage biotechnology companies. An investment in our securities may result in the loss of
the entirety of such investment. Only stockholders and potential stockholders who are experienced in high-risk investments and who can
afford to lose their entire investment should consider an investment in our securities.

Certain
of our founding stockholders, plus our existing officers and directors, control a substantial interest in us and thus may influence certain
actions requiring stockholder vote.

Our
founding stockholders,